Efficacy and Tolerability of Almotriptan in Controlled Clinical Trials
- 1 May 2005
- journal article
- review article
- Published by S. Karger AG in European Neurology
- Vol. 53 (Suppl. 1), 29-33
- https://doi.org/10.1159/000085039
Abstract
Seven triptans are now available for the acute treatment of migraine. While all of these agents have been shown to be safe and more or less well tolerated, they differ in ways that are clinically relevant to individual patients. Almotriptan has been investigated in approximately 3,500 patients enrolled in short-term clinical trials and 1,500 patients enrolled in long-term open-label trials. In a meta-analysis of placebo-controlled almotriptan trials (n = 2,294), treatment with almotriptan 12.5 mg results in a 2-hour pain-relief rate of 63.7% and a 2-hour pain-free rate of 36.4%. Almotriptan is associated with a rapid onset of action, with 30-min pain-relief and pain-free rates significantly better than placebo (p < 0.05). Direct comparator studies show the efficacy of almotriptan 12.5 mg to be comparable to that of sumatriptan but almotriptan is associated with superior tolerability. Trials assessing the efficacy of almotriptan over multiple attacks show that this agent is associated with a consistent and persistent response, not differing from the first to the last attack, an important property for a medication used to treat a chronic condition such as migraine. Early intervention with almotriptan enhances the activity of this agent. Treatment of mild pain with almotriptan has resulted in 2-hour pain-free rates of 84 and 77% and a sustained pain-free rate of 67%. Early treatment (within 1 h) of moderate to severe headaches with almotriptan also improves outcomes. In conclusion, clinical trials and post hoc analyses of such trials have shown almotriptan to be effective and well tolerated for the acute treatment of migraine. Its placebo-like tolerability makes it a good choice for early intervention, a strategy associated with better patient outcomes.This publication has 11 references indexed in Scilit:
- Almotriptan Improves Response Rates When Treatment Is Within 1 Hour of Migraine OnsetHeadache: The Journal of Head and Face Pain, 2004
- Early intervention with almotriptan improves sustained pain-free response in acute migraine.Headache: The Journal of Head and Face Pain, 2003
- A review of the clinical efficacy and tolerability of almotriptan in acute migraineExpert Opinion on Pharmacotherapy, 2003
- Triptans (Serotonin, 5-HT1B/1DAgonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 TrialsCephalalgia, 2002
- Almotriptan is an Effective and Well-Tolerated Treatment for Migraine Pain: Results of A Randomized, Double-Blind, Placebo-Controlled Clinical TrialCephalalgia, 2002
- Within‐Patient Early Versus Delayed Treatment of Migraine Attacks With Almotriptan: The Sooner the BetterHeadache: The Journal of Head and Face Pain, 2002
- Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraineNeurology, 2001
- Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trialsThe Lancet, 2001
- Oral Almotriptan vs Oral Sumatriptan in the Abortive Treatment of MigraineArchives of Neurology, 2001
- Tolerability and Efficacy of Almotriptan in the Long-Term Treatment of MigraineEuropean Neurology, 2001